Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer
Bilgin, Burak, endur, Mehmet AN, H zal, Mutlu, Ak nc, Muhammed Bülent, ener Dede, Didem, Yalç n, Bulent
Published in Future oncology (London, England) (01.09.2017)
Published in Future oncology (London, England) (01.09.2017)
Get full text
Journal Article
The current status of adjuvant treatment for high-risk renal cell carcinoma
H zal, Mutlu, endur, Mehmet AN, Bilgin, Burak, Ak nc, Muhammed Bülent, ener Dede, Didem, Yalç n, Bulent
Published in Future oncology (London, England) (01.10.2017)
Published in Future oncology (London, England) (01.10.2017)
Get full text
Journal Article
Do all aromatase inhibitors have similar efficacy and safety?
endur, Mehmet AN, Bilgin, Burak, H zal, Mutlu, Özdemir, Nuriye Y ld r m, Ak nc, Muhammed Bülent, Dede, Didem ener, Yalç n, Bulent
Published in Future oncology (London, England) (01.08.2017)
Published in Future oncology (London, England) (01.08.2017)
Get full text
Journal Article
Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer
endur, Mehmet Ali Nahit, Aksoy, Sercan, Bülent Ak nc, Muhammed, Ozdemir, Nuriye, ener Dede, Didem, Altundag, Kadri, Zengin, Nurullah, Yalç n, Bülent
Published in Future oncology (London, England) (01.03.2015)
Published in Future oncology (London, England) (01.03.2015)
Get full text
Journal Article